Medication info

Zadiel Tablet 25 mg (Empagliflozin)

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Empagliflozin›25mg / 1 tablet
Manufacturer / importer
GL Pharm Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
10 tablets/PTP [10 tablets/PTP×1], 30 tablets/PTP [10 tablets/PTP×3]
Approval status
Approval withdrawn

MFDS item code 202105979 · Approved 2021.08.17

This product's status changed to Approval withdrawn on 2026.01.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 10 mg once daily, as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, 4. General Precautions).

Ingredients

Manufacturer
GL Pharm Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes mellitus

  • Abnormal blood sugar control in patients with type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. It can be used alone or in combination with other medications. Additionally, for patients with type 2 diabetes who are not adequately controlled and have cardiovascular disease, caution is necessary regarding the risk of cardiovascular events, hence clinical trial information from a professional should be considered. This medication is effectively used in diabetes management.

How to take

Adult dose

The recommended dose of this medicine is 10 mg once daily, as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, 4. General Precautions).

Precautions

This medication should not be used in certain patients. Firstly, individuals with allergic reactions to any components of this medication should not take it. Secondly, patients with type 1 diabetes or diabetic ketoacidosis should not use this medication. Thirdly, patients with severely impaired renal function or those on dialysis should also avoid this medication. Fourthly, patients with genetic lactose intolerance or lactase deficiency, and glucose-galactose malabsorption should avoid this medication. This medication should be used with caution in patients with impaired renal function, and if renal function drops below a certain level, the medication should be discontinued. Particularly, in patients with end-stage renal disease or those on dialysis, the expected effect of this medication is not anticipated, so it is not used. In patients with mild to moderate heart failure, this medication should be used with caution, while it is not recommended for patients with severe heart failure. When this medication is used in conjunction with insulin or insulin secretagogues, there is a risk of hypoglycemia, necessitating the adjustment of dosages of these medications. During treatment, side effects such as hypoglycemia, infections, increased urination, and decreased fluid volume may occur, so caution is advised. In particular, genital infections and urinary tract infections may increase, so if symptoms occur, it is crucial to consult a doctor immediately. This medication can cause severe ketoacidosis; if suspected symptoms occur, immediate treatment should be sought, and medication discontinuation should follow if necessary. Elderly patients or those at risk for fluid volume loss should be cautious of dehydration or hypotension, with regular fluid status checks being important. Pregnant women are advised to avoid this medication, and if pregnancy is confirmed, it should be discontinued immediately. Breastfeeding women are also recommended to cease nursing during the use of this medication. Children and adolescents should not use this medication as its safety and efficacy have not been established. No specific toxicity has been reported for overdose, but if abnormal symptoms occur, immediate medical attention should be sought for appropriate treatment. Lastly, this medication may interact with other drugs, so it's important to inform healthcare professionals of any other medications being taken. Finally, this medication should be stored out of reach of children, and transferring it to another container should be avoided.

Side effects

  • Hypoglycemia
  • vulvovaginitis
  • balanitis and other genital infections
  • urinary tract infections
  • perineal necrosis
  • ketoacidosis
  • pruritus
  • rash
  • urticaria
  • angioedema
Show 11 more
  • decreased fluid volume
  • increased urination
  • urinary difficulty
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in an airtight container to prevent exposure to air or moisture, and it is best kept at room temperature between 1 to 30 degrees Celsius. Therefore, it should be securely stored away from overly hot or cold places.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

10 tablets/PTP [10 tablets/PTP×1], 30 tablets/PTP [10 tablets/PTP×3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.